| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.09 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.09 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.09 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.077 | 0.09 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.066 | 0.09 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.071 | 0.09 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |